

Distribution of Amino Acid Activating Enzymes in Rabbit's Brain

In order to understand the brain function, it is considered to be necessary to study the regional pattern of enzymes and many compounds. Recently, the localization of protein metabolism in various brain areas has been studied by several investigators¹⁻³; however, little work has been done to study regional distribution of individual enzymes participating in protein metabolism of the brain. LAJTHA⁴ reported the distribution of proteinase activity in various brain areas. The present report describes some results on the distribution of amino acid activating enzymes in various brain areas, as one of our reports on the protein metabolism of brain tissue⁵⁻⁸.

Rabbits weighing about 2.5 kg were killed by decapitation. The brains were removed immediately and cerebral cortex, cerebral white matter, hippocampus, hypothalamus, midbrain, cerebellum, medulla-pons and spinal cord were isolated. A portion of each tissue was transferred to a glass homogenizer tube and homogenized in one volume of medium A⁹. The homogenates were separated into a soluble fraction and a centrifugal residue by centrifugation for 90 min at 105 000 g in a Spinco L centrifuge. A soluble fraction was used for the assay of amino acid activating enzymes. The assay procedures for amino acid activating enzymes were carried out using PP³²-ATP exchange method. 1 ml of incubation mixture for the PP³²-ATP exchange contained 3 μ moles ATP, 10 μ moles MgCl₂, 3 μ moles PP³² containing about 100 000 counts/min, 100 μ moles Tris buffer, pH 7.8, an amino acid mixture containing 3 μ moles of each of 20 amino acids and the enzyme fraction. Incubation was carried out at 37° for 15 min. After incubation, the reaction was stopped with cold TCA (final concentration 5%) and PP and ATP were separated by charcoal absorption according to the method of CRANE and LIPMANN¹⁰. The concentration and radioactivities of ATP and pp were estimated as orthophosphate after these compounds had been hydrolysed in 1N H₂SO₄ for 15 min at 100°C. The determination of inorganic phosphate was that of FISKE and SUBBAROW¹¹. The radioactivity was determined with a RIDL Model 21 gas flow counter. The data were expressed as percent exchange according to HOAGLAND et al.¹². P³² was obtained from Radiochemical Centre, Amersham, England. P³² labelled inorganic pyrophosphate (PP³²) was prepared by the method of KORNBERG and PRICER¹³ and purified according to the modified procedure of COHN and CARTER¹⁴. Radiochemical analysis of the products showed that the contamination of P³² orthophosphate was less than 1%.

PP³²-ATP exchange reaction of the cell sap of rabbit brain areas was observed to be slight in the absence of amino acids. PP³²-ATP exchange reaction of the spinal cord in absence of the amino acid mixture was rather high; among various brain areas, however, little significant differences between various areas were observed (Table).

A rapid PP³²-ATP exchange reaction of the cell sap of various brain areas was observed in the presence of the amino acid mixture. While PP³²-ATP exchange of cerebral cortex and medulla-pons was more active, that of white matter, hippocampus and cerebellum was less active.

Increase in PP³²-ATP% exchange in the presence of an amino acid mixture was also shown in the Table. This increase may be regarded as the true activity of the amino acid activating enzymes. The value of cerebral cortex was highest, while that of cerebral white matter was lowest. Cerebellum, medulla-pons, midbrain and hippocampus showed intermediate values, and spinal cord a

rather low value. The experimental number of hypothalamus was low.

The presence of amino acid activating enzymes in brain cell sap was first observed using hydroxamate method by LIPMANN¹⁵ and general characteristics of these enzymes in brain were studied by our group¹⁶. When a comparison of the distribution of amino acid activating enzymes in various brain areas of rabbit was made with the results of the incorporation of radioactive amino acid

PP³²-ATP exchange in cell sap of different areas of rabbit's brain

Areas ^a	PP ³² -ATP % exchange ^b		% Variation from cerebral cortex
	Amino acid mixture (+)	Amino acid mixture (—)	
Cerebral cortex	33.2	8.1	25.1
Cerebral white matter	25.5	10.3	15.2
Cerebellum	27.6	8.2	19.4
Medulla-Pons	33.5	11.3	22.2
Midbrain	30.7	10.1	20.6
Hypothalamus	27.2	7.5	19.7
Hippocampus	26.1	8.4	17.7
Spinal cord	29.9	12.5	17.4

^a The values are means of 4-5 experiments except for hypothalamus (2 experiments). ^b PP³²-ATP % exchange/mg protein. ^c Increase due to addition of the amino acid mixture.

into the protein of various brain areas by various authors, including our group¹⁷, some parallelism exists in that the high incorporation is in the cerebral cortex and the amino acid activating enzymes are also more active. In cerebral white matter and spinal cord, there is low incorporation and low amino acid activating enzyme activities. However, hippocampus showed high incorporation and inter-

¹ D. RICHTER, M. K. GAITONDE, and P. COHN, *Structure and Function of the Cerebral Cortex* (Ed. by D. B. TOWER and J. P. SCHADE, Elsevier Publishing Company, Amsterdam 1960), p. 340.

² A. V. PALLADIN, N. M. POLIAKOVA, and J. P. SILICH, *Fiziol. Zhur. S.S.S.R.* **43**, 611 (1957).

³ S. FURST, A. LAJTHA, and H. WAELSCH, *J. Neurochem.* **2**, 216 (1958).

⁴ A. LAJTHA, *Regional Neurochemistry* (Ed. by S. S. KETY and J. ELKES, Pergamon Press, Oxford 1961), p. 25.

⁵ Y. TAKAHASHI and Y. AKABANE, *Canad. J. Biochem. Physiol.* **38**, 1149 (1960).

⁶ M. SATAKE, K. MASE, Y. TAKAHASHI, and K. OGATA, *Biochim. biophys. Acta* **41**, 366 (1960).

⁷ Y. TAKAHASHI, M. NOMURA, and S. FURUSAWA, *J. Neurochem.* **7**, 97 (1961).

⁸ K. MASE, Y. TAKAHASHI, and K. OGATA, *J. Neurochem.* **9**, 281 (1962).

⁹ J. W. LITTLEFIELD and E. B. KELLER, *J. biol. Chem.* **224**, 13 (1957).

¹⁰ R. K. CRANE and F. LIPMANN, *J. biol. Chem.* **201**, 235 (1953).

¹¹ C. H. FISKE and Y. SUBBAROW, *J. biol. Chem.* **66**, 375 (1925).

¹² M. B. HOAGLAND, E. B. KELLER, and P. C. ZAMECNIK, *J. biol. Chem.* **218**, 345 (1956).

¹³ A. KORNBERG and W. E. PRICER, *J. biol. Chem.* **191**, 535 (1951).

¹⁴ W. E. COHN and C. E. CARTER, *J. Amer. chem. Soc.* **72**, 4273 (1950).

¹⁵ F. LIPMANN, *Metabolism of the Nervous System* (Ed. by D. RICHTER, Pergamon Press, Oxford 1957), p. 329.

¹⁶ Y. TAKAHASHI, K. MASE, M. SATAKE, and K. OGATA, *J. Jap. Biochem. Society* **33**, 649 (1961).

¹⁷ K. MASE and Y. TAKAHASHI, *Rec. Advances Neurol. Res.* **4**, 597 (1960).

mediate amino acid activating enzymes activities. The amino acid activating enzymes of cerebellum, medulla, and midbrain did not show differences as significant as the incorporation results of the protein of these areas. It seems possible that the results with amino acid activating enzymes represent differences in the enzymes content or variation in the stability of these enzymes. It is not surprising that parallelism does not generally exist between the incorporation results and amino acid activating enzymes activities of various brain areas. Amino acid activating enzymes may not be the limiting factor in protein biosynthesis and may be present in excess to incorporate a radioactive amino acid into proteins of the various brain areas. More definite differences may be in the activity and content of ribosome and transfer enzymes in various brain areas¹⁸.

Zusammenfassung. Untersuchungen an Aminosäure-aktivierenden Fermenten in den diversen Kaninchenhirnregionen, haben gezeigt, dass die Aktivität der Gross-

hirnrinde am höchsten, die der weissen Substanz des Grosshirns am niedrigsten ist, während sie in den übrigen Hirnteilen in der Mitte liegt.

Y. TAKAHASHI¹⁹ and S. ABE

Brain Research Institute, Niigata University School of Medicine, Niigata (Japan), November 13, 1962.

¹⁸ The authors are very grateful to Dr. K. OGATA and Dr. K. ISHIKAWA (Department of Biochemistry, Niigata University School of Medicine, Japan) for making some samples of PP₃₂ available and to Dr. FUSE (Department of Anatomy, Niigata University School of Medicine, Japan) and Dr. T. KON (Brain Research Institute, Niigata University School of Medicine, Japan) for their dissection of brain areas. The authors also wish to thank Dr. L. C. MOKRASCH and Mrs. P. MANNER (McLean Hospital, Belmont, Massachusetts, U.S.A.) for kindly reading this paper.

¹⁹ Present address: McLean Hospital Research Laboratory, Belmont (Massachusetts, U.S.A.): to whom requires concerning this paper should be addressed.

5-Hydroxytryptamine Content of Glioma

It is not known whether 5-HT is located in excitable neural tissue or in other types of cell in the central nervous system. The results of experiments in which C¹⁴ labelled 5-hydroxytryptophan (5-HTP) was injected into animals and its subsequent distribution on autoradiographs examined¹ have suggested that 5-HT may be contained in the glial cells and that its chief action is on the blood vessels around which glial cells cluster.

Information relevant to the location of 5-HT in the central nervous system may also be sought in the 5-HT content of cerebral neoplasms of different cell types and the present study compares estimates of 5-HT in human tissues classified as 'normal' cerebral cortex, 'glioma' and 'meningioma'.

Neoplastic tissues were obtained from two female and five male patients at the time of operation. Their ages ranged from 19 to 71 years. The neoplastic tissues were all from cerebral cortical areas except in case No. 4 where the tumour involved the basal ganglia. The tumours were classified by histological examination of a piece of abnormal tissue adjoining that used for the pharmacological examination. Samples of normal cerebral cortical tissue were also obtained when their removal was necessary for access to the tumour.

The tissues on which 5-HT estimations were to be carried out were collected directly from the operating theatre in containers at 0°C. Pieces of approximately 1 g in weight were extracted with four volumes of acetone according to CORREALE² and within 30 min of removal from the body. The brain extracts were taken up in distilled water and assayed biologically on the rat stomach by the method of VANE³. The potency of each individual extract was estimated at least four times. Hyoscine 10⁻⁷ was present in the bathing solution and the active substance assayed was identified as 5-HT by the action of BOL 10⁻⁷ at the end of each experiment. The methods used have already been fully described⁴.

It was necessary to confirm that 5-HT loss after surgical removal occurs at the same rate in normal and neoplastic tissues. Normal tissue left at room temperature (20°C) lost 19% of its 5-hydroxytryptamine content in 24 h whereas the glioma lost 27%. These values are of the same

order as those previously reported for cerebral cortical tissues⁴.

The results in the Table show the mean 5-HT concentration of extracts from several tissue samples from the same patient. With one exception (case No. 4) and regardless of the nature of the tumour, 5-HT concentrations were found to be lower in the neoplasm than in the adjacent cerebral cortex. The one neoplasm which showed a higher concentration of 5-HT differed from the others in that the tumour involved the basal ganglia. This patient had also previously received high doses of antibiotic (penicillin and streptomycin) and although the oral administration of antibiotics has been found to cause an increase in platelet 5-HT⁵ but not of brain 5-HT, the possibility must be considered that if a rise in platelet 5-HT does occur, the concentration of 5-HT may consequently increase in an area such as a neoplasm where the blood brain barrier has suffered a local breakdown. The most pronounced behavioural disturbance was also seen in this patient (No. 4)

5-Hydroxytryptamine (5-HT) concentrations in normal and pathological tissues

Patient No.	Age	Sex	Tumour	5-HT mean ng/g wet weight \pm SE (n)		
				Normal frontal lobe	Temporal lobe	Tumour
1	67	F	Meningioma	36.5 \pm 3.5 (2)		18.5 \pm 3.5 (2)
2	59	M	Meningioma	38.0 (1)		23.5 \pm 1.7 (4)
3	23	F	Glioma	54.5 \pm 7.5 (2)		20.5 \pm 3.5 (2)
4	71	M	Glioma	30.0 (1)		84.3 \pm 5.5 (3)
5	27	M	Glioma	59.3 \pm 8.1 (4)		31.1 \pm 2.8 (5)
6	39	M	Glioma		47.5 \pm 3.5 (2)	29.7 \pm 0.5 (3)
7	19	M	Oligodendro-glioma			16.0 \pm 1.0 (2)

¹ G. P. LEWIS, J. Pharm. Lond. 10, 529 (1958).

² P. CORREALE, J. Neurochem. 1, 22 (1956).

³ J. R. VANE, Brit. J. Pharmacol. 12, 344 (1957).

⁴ D. JOYCE, Brit. J. Pharmacol. 18, 370 (1962).

⁵ T. J. SULLIVAN, Brit. J. Pharmacol. 12, 344 (1961).